Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium. Scott SA, et al. Among authors: mega jl. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22. Clin Pharmacol Ther. 2013. PMID: 23698643 Free PMC article.
CYP2C19 genotype and cardiovascular events.
Mega JL, Topol EJ, Sabatine MS. Mega JL, et al. JAMA. 2012 Apr 11;307(14):1482-3; author reply 1484-5. doi: 10.1001/jama.2012.444. JAMA. 2012. PMID: 22496256 No abstract available.
Pharmacogenomics of antiplatelet drugs.
Sabatine MS, Mega JL. Sabatine MS, et al. Among authors: mega jl. Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):343-7. doi: 10.1182/asheducation-2014.1.343. Epub 2014 Nov 18. Hematology Am Soc Hematol Educ Program. 2014. PMID: 25696877 Review.
PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes.
Mega JL, Close SL, Wiviott SD, Man M, Duvvuru S, Walker JR, Sundseth SS, Collet JP, Delaney JT, Hulot JS, Murphy SA, Paré G, Price MJ, Sibbing D, Simon T, Trenk D, Antman EM, Sabatine MS. Mega JL, et al. J Thromb Thrombolysis. 2016 Apr;41(3):374-83. doi: 10.1007/s11239-015-1264-9. J Thromb Thrombolysis. 2016. PMID: 26573179
Cytochrome p-450 polymorphisms and response to clopidogrel.
Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Mega JL, et al. N Engl J Med. 2009 Jan 22;360(4):354-62. doi: 10.1056/NEJMoa0809171. Epub 2008 Dec 22. N Engl J Med. 2009. PMID: 19106084 Free article.
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Mega JL, et al. JAMA. 2010 Oct 27;304(16):1821-30. doi: 10.1001/jama.2010.1543. JAMA. 2010. PMID: 20978260 Free PMC article.
80 results